26 results on '"Hertel, Nadine"'
Search Results
2. Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways
3. Non-Price-Related Determinants of Value and Access for Novel Non-small Cell Lung Cancer Treatments: A Cross-Country Review of HTA Decision Making
4. Performance of international prognostic indices in plasmablastic lymphoma: a comparative evaluation
5. The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England
6. An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference?
7. Clinicopathological characteristics and MYC status determine treatment outcome in plasmablastic lymphoma: a multi-center study of 76 consecutive patients
8. Primary refractory plasmablastic lymphoma: A precision oncology approach
9. The present and future burden of previously treated advanced non-small cell lung cancer (NSCLC) by histology and line of therapy in France, Germany, Italy, and Spain: model-based predictions
10. Cost-Effectiveness of Tapentadol in Severe Chronic Pain in Spain: A Cost Analysis of Data From RCTs
11. Costs and Cost Drivers Associated with Non-Small-Cell Lung Cancer Patients Who Received Two or More Lines of Therapy in Europe
12. Cost-Effectiveness of Strong Opioids Focussing on the Long-Term Effects of Opioid-Related Fractures: A Model Approach
13. Cost-Effectiveness Analysis of a Lidocaine 5% Medicated Plaster Compared with Gabapentin and Pregabalin for Treating Postherpetic Neuralgia: A German Perspective
14. Costs and Cost Drivers Associated with Non-Small-Cell Lung Cancer Patients Who Received Two or More Lines of Therapy in Europe
15. An economic evaluation of nivolumab for the treatment of squamous and non-squamous NSCLC in the Swedish setting
16. Additional file 2: of The present and future burden of previously treated advanced non-small cell lung cancer (NSCLC) by histology and line of therapy in France, Germany, Italy, and Spain: model-based predictions
17. Additional file 1: of The present and future burden of previously treated advanced non-small cell lung cancer (NSCLC) by histology and line of therapy in France, Germany, Italy, and Spain: model-based predictions
18. The Cost of Costing Treatments Incorrectly: Errors in the Application of Drug Prices in Economic Evaluation Due to Failing to Account for the Distribution of Patient Weight
19. P2.03b-097 Prognostic Factors for Overall Survival among Patients with Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
20. Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis
21. Cost-effectiveness of tapentadol prolonged release compared with oxycodone controlled release in the UK in patients with severe non-malignant chronic pain who failed 1st line treatment with morphine
22. Cost-effectiveness of strong opioids focussing on the long-term effects of opioid-related fractures: a model approach
23. Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis.
24. Cost-effectiveness of strong opioids focussing on the long-term effects of opioid-related fractures: a model approach.
25. Cost-effectiveness of Nivolumab in Patients With NSCLC in the United States.
26. Cost-effectiveness of strong opioids focussing on the long-term effects of opioid-related fractures: a model approach.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.